Transcode Therapeutics (RNAZ) Cash from Operations (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Cash from Operations came in at 5000000.0 in Q1 2026, down 61.46% YoY from 12974152.31 in Q1 2025, and up 38.59% on a QoQ basis from 8142010.0 in Q4 2025.
Transcode Therapeutics (RNAZ) Cash from Operations (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Cash from Operations data on file, last reported at 5000000.0 in Q1 2026.
- Quarterly Cash from Operations fell 61.46% year-over-year to 5000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21419522.0 (down 71.42% YoY) and the FY2025 annual result came in at 19516229.0, down 46.34% from the prior year.
- Cash from Operations improved to 5000000.0 in Q1 2026, from 8142010.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 2339768.0 in Q2 2024 to a low of 8142010.0 in Q4 2025.
- A 5-year average of 4217013.12 and a median of 4019724.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations tumbled 4337.16% — and 2024, when it soared 46.72%.
- Tracing RNAZ's Cash from Operations over 5 years: stood at 4019724.0 in 2022, then slumped by 40.89% to 5663489.0 in 2023, then soared by 44.45% to 3146337.0 in 2024, then plunged by 158.78% to 8142010.0 in 2025, then soared by 38.59% to 5000000.0 in 2026.
- The last three Cash from Operations figures came in at 5000000.0 (Q1 2026), 8142010.0 (Q4 2025), and 4083173.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 728.46 Mn |
| 10 | Transcode Therapeutics | 2.85 Mn | 2.85 Mn | - | -5.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.00 Mn |
| Mar 31, 2026 | -5.00 Mn |
| Dec 31, 2025 | -8.14 Mn |
| Dec 31, 2025 | -8.14 Mn |
| Sep 30, 2025 | -4.08 Mn |
| Sep 30, 2025 | -4.08 Mn |
| Jun 30, 2025 | -4.19 Mn |
| Jun 30, 2025 | -4.19 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Dec 31, 2024 | -3.15 Mn |
| Dec 31, 2024 | -3.15 Mn |
| Sep 30, 2024 | -3.91 Mn |
| Sep 30, 2024 | -3.91 Mn |
| Jun 30, 2024 | -2.34 Mn |
| Jun 30, 2024 | -2.34 Mn |
| Mar 31, 2024 | -3.94 Mn |
| Mar 31, 2024 | -3.94 Mn |
| Dec 31, 2023 | -5.66 Mn |
| Dec 31, 2023 | -5.66 Mn |